Skip to Main Content

Rise and shine, everyone, another busy day is on the way. Yes, indeed, the middle of the week is already here, which means there is much to do. No doubt, you can relate on some level. So please join us as we grab a cup of stimulation — remember, no prescription is required — and tackle the Zoom and Skype calls and deadlines that are piling up. Meanwhile, here is the latest grab bag of items to help you along. Hope you conquer the world today, and do stay in touch. …

The National Institutes of Health is launching studies of monoclonal antibodies in patients with mild to moderate Covid-19, CNBC tells us. The trials re part of a government-industry collaboration known as ACTIV, for Accelerating Covid-19 Therapeutic Interventions and Vaccines, and will look an experimental Eli Lilly (LLY) treatment that is being developed with AbCellera. Earlier this week, the company began a Phase 3 trial testing whether the treatment can prevent the spread of Covid-19 in nursing home residents and staff.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!